belimumab

Base Information

• Chemical Name: belimumab
• CAS No.: 356547-88-1
• Molecular Weight: 0
• Mol file: 356547-88-1.mol

Synonyms:Belimumab;Immunoglobulin G1, anti-(human BLyS) (human monoclonal LymphoStat-B heavychain), disulfide with human monoclonal LymphoStat-B l-chain,dimer; LymphoStat B

Chemical Property of belimumab

Chemical Property:

• PSA: 0.00000
• LogP: 0.00000

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Description: Belimumab was approved by the U.S. FDA in March 2011 for treatment of patients with active, autoantibody-positive, systemic lupus erythematosus (SLE). Belimumab is a human sequence monoclonal antibody that binds to human B lymphocyte stimulator protein (BLys; also known as BAFF, THANK, TALL-1, TNFSF13B, and zTNF4), which is overexpressed in SLE patients. BLys is expressed on the cell surface of monocytes, macrophages, and monocyte-derived dendritic cells and is cleaved to form a soluble cytokine that stimulates cell proliferation and antibody secretion in B lineage cells that express the BLys receptor BAFF-R (also known as BR-3). The precise function of two additional BLys receptors, TACI and BCMA, is less clear. Belimumab inhibits BLys interaction with these three receptors leading to measurable reductions in autoantibodies, such as anti-dsDNA, and specific circulating B cell lineage compartments including antibody producing plasma cells. Belimumab was discovered by screening molecules from a phage display library of human single-chain Fv sequences for BLys binding and functional blocking, followed by optimization of the lead through the introduction of variant residues in VH CDR3.
• Uses: Treatment of autoimmune disease.
• Clinical Use: Anti-lymphocyte monoclonal antibody: Treatment of systemic lupus erythematosus
• Drug interactions: Potentially hazardous interactions with other drugs Live vaccines: avoid concomitant use.